Physician profile
Frederick Dold
NPI 1174638597
$16,116.14
in general payments reported to CMS, 2019-2025
89 companies · $2,981 in 2025
The $2,981 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,879 · 2020: $934 · 2021: $1,458 · 2022: $2,240 · 2023: $2,879 · 2024: $2,745 · 2025: $2,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,389 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,389.34 |
| Education | $215.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,231.42 | 2019-2025 | |
| Janssen Biotech, INC. | $892.62 | 2019-2025 | Darzalex, Talvey, Erleada |
| Astrazeneca Pharmaceuticals LP | $715.06 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Genzyme Corporation | $670.17 | 2019-2025 | |
| Genentech USA, INC. | $668.70 | 2019-2025 | Polivy, Venclexta, Tecentriq Hybreza |
| Eisai INC. | $631.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $618.84 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Merck Sharp & Dohme LLC | $586.81 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $567.19 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $476.76 | 2019-2025 | |
| Abbvie INC. | $445.30 | 2019-2025 | Venclexta |
| Amgen INC. | $440.94 | 2019-2023 | Kyprolis, Blincyto, Nplate |
| Bayer Healthcare Pharmaceuticals INC. | $427.61 | 2019-2025 | |
| Daiichi Sankyo INC. | $426.28 | 2019-2025 | Enhertu, Injectafer |
| Incyte Corporation | $420.79 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $399.15 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $344.06 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Paratek Pharmaceuticals, INC. | $332.41 | 2020-2023 | Nuzyra |
| Seagen INC. | $294.38 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $281.29 | 2019-2025 | Ninlaro, Hyqvia, Vpriv |
| Alexion Pharmaceuticals, INC. | $259.75 | 2019-2025 | Ultomiris, Soliris |
| Pharmacyclics LLC, An Abbvie Company | $238.73 | 2019-2023 | Imbruvica, Epkinly |
| Eagle Pharmaceuticals, INC. | $204.41 | 2023-2024 | |
| Genmab U.S., INC. | $201.78 | 2022-2025 | Tivdak, Epkinly |
| Puma Biotechnology, INC. | $194.59 | 2019-2024 | |
| Gilead Sciences, INC. | $170.17 | 2019-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $163.38 | 2020-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $162.95 | 2019-2025 | Somatuline Depot, Onivyde |
| Tesaro, INC. | $157.39 | 2019 | |
| Karyopharm Therapeutics INC. | $141.27 | 2023-2025 | Xpovio |
| Emd Serono, INC. | $130.96 | 2019-2024 | Bavencio |
| Foundation Medicine, INC. | $121.73 | 2019-2023 | |
| Sobi, INC | $121.52 | 2024-2025 | |
| Exelixis INC. | $118.59 | 2019-2025 | Cabometyx |
| Morphosys, US INC. | $114.84 | 2021-2023 | Monjuvi |
| Glaxosmithkline, LLC. | $111.61 | 2019-2024 | Ojjaara |
| Kite Pharma, INC. | $111.10 | 2021-2025 | Yescarta |
| Sumitomo Pharma America, INC. | $108.20 | 2023-2025 | Orgovyx |
| Stemline Therapeutics INC. | $106.70 | 2022-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $102.70 | 2021-2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.97 | 2019-2025 | |
| Acrotech Biopharma INC. | $95.33 | 2021-2025 | Beleodaq |
| Blueprint Medicines Corporation | $92.25 | 2022-2024 | Ayvakit |
| Kyowa Kirin, INC. | $84.48 | 2022-2025 | Poteligeo |
| Pharmaessentia USA Corporation | $83.52 | 2024-2025 | Besremi |
| G1 Therapeutics, INC. | $79.77 | 2022-2023 | Cosela |
| Beigene USA, INC. | $77.96 | 2021-2023 | Brukinsa |
| Array Biopharma INC | $77.85 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Myovant Sciences INC. | $77.50 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $76.18 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $73.40 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $72.78 | 2022-2024 | Myrisk |
| Dendreon Pharmaceuticals LLC | $68.21 | 2019-2020 | |
| Mirati Therapeutics, INC. | $67.80 | 2023-2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $67.73 | 2021-2025 | Qinlock, Tgct |
| Cumberland Pharmaceuticals, INC. | $61.50 | 2025 | Sancuso |
| Helsinn Therapeutics (U.S.), INC. | $56.28 | 2019-2021 | |
| Emmaus Medical, INC. | $55.08 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $50.38 | 2024 | Amvuttra |
| Servier Pharmaceuticals LLC | $47.87 | 2022-2025 | |
| Secura Bio, INC. | $45.05 | 2025 | Copiktra |
| Jazz Pharmaceuticals INC. | $44.74 | 2020-2024 | |
| Tersera Therapeutics LLC | $41.71 | 2019-2024 | Zoladex |
| Novocure INC. | $34.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $34.05 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $33.93 | 2024-2025 | Sylvant, Enjaymo |
| Apellis Pharmaceuticals, INC. | $32.97 | 2022-2023 | Empaveli |
| Azurity Pharmaceuticals, INC. | $30.34 | 2025 | Danziten, Vivimusta |
| Immunocore Limited | $30.02 | 2025 | Kimmtrak |
| Immunogen, INC. | $28.88 | 2023 | Elahere |
| Clovis Oncology, INC. | $28.87 | 2019-2020 | |
| Clinigen, INC. | $28.16 | 2019-2020 | |
| Taiho Oncology, INC. | $26.17 | 2019-2022 | |
| Aadi Bioscience, INC. | $24.58 | 2023 | Fyarro |
| Tempus Ai, INC | $23.13 | 2024 | |
| Springworks Therapeutics, INC. | $21.99 | 2025 | Ogsiveo |
| Spectrum Pharmaceuticals INC. | $21.92 | 2023 | Rolvedon |
| Beone Medicines USA, INC. | $21.31 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $21.27 | 2023 | Yonsa, Odomzo |
| Eusa Pharma (US) LLC | $20.94 | 2022 | |
| Dova Pharmaceuticals | $19.17 | 2020 | |
| Organon LLC | $18.22 | 2023 | Ontruzant |
| Heron Therapeutics, INC. | $17.83 | 2022 | |
| Adaptive Biotechnologies Corporation | $17.56 | 2021 | |
| Global Blood Therapeutics, INC. | $16.37 | 2020 | |
| Advanced Accelerator Applications | $16.31 | 2019 | |
| Acceleron Pharma, INC. | $13.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
Lenvima $382Keytruda $278Reblozyl $262Epkinly $232Enhertu $220Imfinzi $212Darzalex $211Pemfexy $204Xtandi $191Lynparza $187Jakafi $178Imbruvica $178Kisqali $173Nubeqa $170Venclexta $167Opdivo $158Verzenio $152Elahere $150Monjuvi $149Scemblix $148Libtayo $143Xpovio $141Orgovyx $139Somatuline Depot $139Onivyde $139Cablivi $137Enjaymo $134Welireg $125Inlyta $118Ultomiris $114Talzenna $105Nuzyra $101Sarclisa $101Soliris $99.99Jaypirca $99.28Ayvakit $96.19Xospata $93.77Krazati $93.56Tivdak $92.39Kyprolis $90.86Padcev $90.77Calquence $89.41Orserdu $88.82Talvey $88.32Erleada $85.12Monoferric $84.23Besremi $83.52Pluvicto $81.32Trodelvy $79.78Carvykti $79.01Doptelet $78.64Adcetris $78.25Polivy $76.61Stivarga $75.23Fabhalta $74.14Xofigo $72.58Pemazyre $72.17Tukysa $70.10Blincyto $69.21Cabometyx $67.41Rezlidhia $63.65Tavalisse $63.65Tecvayli $62.21Sancuso $61.50Ninlaro $59.55Rybrevant $58.53Beleodaq $55.48Ibrance $52.07Amvuttra $50.38Promacta $50.38Vyloy $50.23Retevmo $49.84Vitrakvi $48.59Niktimvo $47.38Copiktra $45.05Piqray $44.97Myrisk $44.90Wayrilz $44.22Opdualag $44.18Cosela $43.73Vonjo $42.88Poteligeo $42.61Mekinist $41.98Bavencio $40.37Brukinsa $39.67Braftovi $37.07Mektovi $37.07Elrexfio $35.62Ojjaara $34.04Hyqvia $33.89Yescarta $32.41Jevtana $31.41Kimmtrak $30.02Qinlock $28.05Elitek $26.46Vpriv $25.57Augtyro $24.76Fyarro $24.58Injectafer $24.33Zynyz $24.16
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Dold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.